datopotamab deruxtecan + cisplatin

*Datopotamab deruxtecan + cisplatin* is an investigational **combination therapy** used in oncology clinical trials, notably for advanced or metastatic non-small cell lung cancer (NSCLC)[1][3][7]. Datopotamab deruxtecan (Dato-DXd, Datroway) is a **TROP2-directed antibody-drug conjugate**, consisting of a monoclonal antibody targeting the TROP2 antigen linked via an enzymatically-cleavable tetrapeptide linker to the cytotoxic payload DXd, a derivative of exatecan and DNA topoisomerase I inhibitor[2][4][6][8]. After binding to TROP2, the ADC is internalized by tumor cells, releasing DXd intracellularly to induce DNA damage and apoptosis[2][4][6][8]. Cisplatin is a platinum-based chemotherapy agent that induces DNA cross-linking and apoptosis in rapidly dividing cells. The combination is under study as part of first-line or subsequent therapy for NSCLC, aiming to leverage the targeted effect of the ADC and the cytotoxic activity of cisplatin[1][3][7].

Other names

datopotamab deruxtecancisplatin